Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 2/20 | 0.39 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 5/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15139319 | 0.92 | MAPT (0.44) | RAB9ANPC1SMN1; SMN2PARP1CNR1 | |
| SCHEMBL349265 | 0.92 | MAPT (0.41) | RAB9ANPC1PARP1CNR1MCHR1 | |
| SCHEMBL349952 | 0.92 | PARP1 (0.39) | RAB9APARP1 | |
| SCHEMBL349410 | 0.89 | RAB9A (0.40) | RAB9ANPC1SMN1; SMN2CNR1KMT2A | |
| SCHEMBL348821 | 0.89 | PARP1 (0.40) | SMN1; SMN2PARP1CNR1KMT2A | |
| SCHEMBL352127 | 0.87 | MAPK1 (0.44) | RAB9ANPC1SMN1; SMN2PARP1CNR1 | |
| SCHEMBL16817211 | 0.87 | TLR2 (0.37) | RAB9ANPC1TLR2TLR1PARP1 | |
| SCHEMBL351334 | 0.84 | MAPK10 (0.41) | NAMPTKMT2A | |
| SCHEMBL351047 | 0.83 | ENPP2 (0.34) | PARP1CNR1NAMPT | |
| SCHEMBL351894 | 0.83 | MAPK10 (0.44) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | claimed |
| US-8497283-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8329907-B2 | Autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANK TER HAFTUNG (DE) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015976-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | RAB9A 1779/4885NPC1 3210/4885SMN1; SMN2 3076/4885 |
| US-20130023556-A1 | AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, LPCAT1 | RAB9A 1779/4885NPC1 3210/4885SMN1; SMN2 3076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.